# Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC

> **NCT05077839** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 184 (estimated)

## Conditions studied

- First-line Treatment
- Advanced Colorectal Cancer

## Interventions

- **DRUG:** Trifluridine/Tipiracil

## Key facts

- **NCT ID:** NCT05077839
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-01
- **Primary completion:** 2024-08-31
- **Final completion:** 2025-08-31
- **Target enrollment:** 184 (ESTIMATED)
- **Last updated:** 2021-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05077839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05077839, "Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05077839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*